FDA To Revise Warning Label On Bone Drugs

Law360, New York (October 13, 2010, 5:08 PM EDT) -- The U.S. Food and Drug Administration is revising the label on bisphosphonate-based osteoporosis drugs to warn consumers that they could raise the risk of a rare type of thigh-bone fracture.

While it is not clear whether the drugs are the cause, atypical femur fractures have been predominantly reported in patients taking bisphosphonates to treat osteoporosis, the FDA said Wednesday.

The FDA also plans to require drug companies to include a medication guide with the drugs informing patients of the possible increased fracture risk.

Bisphosphonates are at...
To view the full article, register now.